三生物标志物分类器——一种预测结直肠癌患者总生存期的新型简单分子风险评分
The 3-Biomarker Classifier-A Novel and Simple Molecular Risk Score Predicting Overall Survival in Patients with Colorectal Cancer.
作者信息
Melling Nathaniel, Fard-Aghaie Mohammad H, Hube-Magg Claudia, Kluth Martina, Simon Ronald, Tachezy Michael, Ghadban Tarik, Reeh Matthias, Izbicki Jakob R, Sauter Guido, Grupp Katharina
机构信息
Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany.
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany.
出版信息
Cancers (Basel). 2024 Sep 22;16(18):3223. doi: 10.3390/cancers16183223.
INTRODUCTION
Several new molecular markers in colorectal carcinomas have been discovered; however, classical histopathological predictors are still being used to predict survival in patients. We present a novel risk score, which uses molecular markers, to predict outcomes in patients with colorectal carcinoma.
METHODS
The immunohistochemistry of tissue micro arrays was used to detect and quantify H2BUB1, RBM3 and Ki-67. Different intensities of staining were categorized for these markers and a score was established. A multivariate analysis was performed and survival curves were established.
RESULTS
1791 patients were evaluated, and multivariate analysis revealed that our risk score, the 3-biomarker classifier, is an independent marker to predict survival. We found a high risk-score to be associated with dismal median survival for the patients.
CONCLUSIONS
A more personalized score might be able to better discriminate low- and high-risk patients and suggest adjuvant treatment compared to classical pathological staging. Our score can serve as a tool to predict outcomes in patients suffering from colorectal carcinoma.
引言
结直肠癌中已发现了几种新的分子标志物；然而，经典的组织病理学预测指标仍被用于预测患者的生存情况。我们提出了一种使用分子标志物的新型风险评分，以预测结直肠癌患者的预后。
方法
采用组织微阵列免疫组化法检测和定量H2BUB1、RBM3和Ki-67。对这些标志物的不同染色强度进行分类并建立评分。进行多变量分析并绘制生存曲线。
结果
对1791例患者进行了评估，多变量分析显示我们的风险评分，即三生物标志物分类器，是预测生存的独立标志物。我们发现高风险评分与患者较差的中位生存期相关。
结论
与经典病理分期相比，更个性化的评分可能能够更好地区分低风险和高风险患者，并指导辅助治疗。我们的评分可作为预测结直肠癌患者预后的工具。
Zotero 插件